MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs

Cell Death and Differentiation

Volumn 19, Issue 6, 2012, Pages 926-936

  Peche, L Y ^a   Scolz, M ^a   Ladelfa, M F ^b   Monte, M ^b   Schneider, C ^a,c  

^a Laboratorio Nazionale del Consorzio Interuniversitario per le Biotecnologie   (Italy)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Acetylation; MAGE; P53; PML; Senescence; Sumoylation

Indexed keywords

MELANOMA ANTIGEN 2; PMLIV PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL AGING; CELL COUNT; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE TARGETING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; ONCOGENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA NUCLEAR BODIES; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SENESCENCE; SUMOYLATION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ACETYLATION; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; FIBROBLASTS; HEK293 CELLS; HISTONE DEACETYLASES; HUMANS; INTRANUCLEAR INCLUSION BODIES; MELANOMA-SPECIFIC ANTIGENS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN INTERACTION MAPPING; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUMOYLATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84860709673     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.173     Document Type: Article

References (40)

1. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61: 5544-5551.
2. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327-7335.
3. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596-604.
4. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
5. Sang M, Wang L, Ding C, Zhou X, Wang B, Lian Y et al. Melanoma-associated antigen genes-an update. Cancer Lett 2011; 302: 85-90.
6. Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D, De Smet C et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004; 32: 4340-4350.
7. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008; 14: 1984-1996.
8. Kondo T, Zhu X, Asa SL, Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007; 13: 4713-4720.
9. Askew EB, Bai S, Hnat AT, Minges JT, Wilson EM. Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem 2009; 284: 34793-34808.
10. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006; 103: 11160-11165.
11. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007; 67: 9954-9962.
12. Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010; 70: 10362-10370.
13. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 2003; 278: 10668-10674.
14. Sakurai T, Itoh K, Higashitsuji H, Nagao T, Nonoguchi K, Chiba T et al. A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem 2004; 279: 15505-15514.
15. Peikert T, Specks U, Farver C, Erzurum SC, Comhair SA. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 2006; 66: 4693-4700.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
17. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14: 2015-2027.
18. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210.
19. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 2007; 8: 1006-1016.
20. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb Perspect Biol 2010; 2: a000661.
21. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000; 19: 6185-6195.
22. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PMLinduced premature senescence. EMBO J 2002; 21: 3358-3369.
23. Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem 2008; 283: 24420-24425.
24. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol 2000; 2: 730-736.
25. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
26. Reineke EL, Kao HY. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int J Biol Sci 2009; 5: 366-376.
27. Nichol JN, Petruccelli LA, Miller Jr WH. Expanding PML's functional repertoire through post-translational mechanisms. Front Biosci 2009; 14: 2293-2306.
28. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. Role of SUMO-1-modified PML in nuclear body formation. Blood 2000; 95: 2748-2752.
29. Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nature Cell Biol 2010; 12: 380-389.
30. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
31. LiuW, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 mediates fibronectincontrolled cancer progression and metastasis. Cancer Res 2008; 68: 8104-8112.
32. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010; 95: 785-793.
33. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009; 69: 616-624.
34. Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N et al. Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep 2007; 18: 329-336.
35. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S et al. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 2001; 21: 2259-2268.
36. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193: 1361-1371.
37. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nature Cell Biol 2008; 10: 547-555.
38. Doyle JM, Gao J, Wang J, Yang M, Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010; 39: 963-974.
39. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21: 2383-2396.
40. Bischof O, Nacerddine K, Dejean A. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol Cell Biol 2005; 25: 1013-1024.